Leah Morris has been using birth control since her teenage years. She recalls her initial appointment as straightforward, simply being told it was time for her to start. She commenced taking Yasmine, a popular estrogen-based oral contraceptive, and initially, refills were easily obtained from her local pharmacy. However, as Morris ventured globally for her work in international development and venture capital, acquiring a prescription became challenging at times. She expressed frustration, saying, “I have to keep going back to my doctor and proving I haven’t had any adverse effects. It’s a significant time-consuming process.”
In Canada, oral contraceptives are the predominant birth control method among women, but they are only accessible through a prescription, a distinct scenario compared to many other nations. Beyond Western Europe, countries like Canada, New Zealand, Australia, and South Africa, birth control is commonly available without a prescription, even in conservative nations like Saudi Arabia, Turkey, or Indonesia. In the United States, where reproductive rights are often contentious, non-prescription birth control has been available since 2023.
The reason Canada still lags in this regard is multifaceted. Since 1960, most oral birth control methods have been “combined pills,” containing estrogen and progestin to prevent ovulation. These pills, such as Yasmine, come with side effects like bloating and headaches, as well as risks such as cervical cancer and blood clots, which escalate with age. Consequently, medical professionals often recommend ongoing monitoring.
While prescription-free birth control alternatives are increasingly entering the market globally, many no longer rely on estrogen. Progestin-only pills, like Opill, function by thickening cervical mucus to impede sperm from fertilizing an egg. Though these pills demand stricter adherence to dosing schedules, they are deemed safer to use without medical supervision.
Dr. Wendy Norman, a sexual health researcher at the University of British Columbia, highlighted that countries tolerating higher medical risks, typically developing nations, permit prescription-free access to combined pills. However, the stringent approval process for making drugs available over-the-counter poses challenges for companies.
Norman advocated for keeping birth control prescription-only, emphasizing that prescription drugs are covered by the healthcare system. Yet, despite efforts to include free contraception in the national pharmacare plan, accessibility remains limited across most Canadian provinces and territories. The requirement for prescriptions may hinder women’s access to birth control, especially marginalized communities.
Kelly Blanchard, involved in the Free the Pill campaign, underscored that eliminating prescription requirements could enhance contraceptive access. Research suggests that making birth control available over-the-counter led to a significant increase in new users. She contended that prescription mandates disproportionately impede women’s access to birth control, especially among minority groups.
In conclusion, there is mounting evidence supporting the safety and efficacy of birth control methods, challenging the outdated rationale behind prescription requirements. Blanchard called for a reevaluation of regulatory systems, suggesting that adherence to prescription-based models may stem from outdated biases in women’s healthcare.
